Diary - News
All news First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line
Valneva to begin receiving royalties for an EB66®-based human vaccine in
Valneva SE (“Valneva” or “the Company”), a leading pure play vaccine company, announces today that GlaxoSmithKline (GSK) in collaboration with one of its partners has for the first time supplied pre-pandemic influenza vaccines based on Valneva’s EB66® cell line.
